Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Pancreatic cancer is a leading cause of cancer death globally, with low survival rates, especially in advanced stages.
• Conventional chemotherapy offers limited efficacy, necessitating novel therapeutic strategies.
• Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors have emerged as a promising targeted therapy, particularly for DNA damage repair (DDR) mutations.

Purpose of the Study:

• To review current clinical trials investigating PARP inhibitors in pancreatic cancer.
• To explore the efficacy of PARP inhibitors across various DNA damage repair (DDR) mutations.
• To summarize evolving treatment strategies involving PARP inhibitors in pancreatic cancer management.

Main Methods:

• Review of ongoing and recently completed clinical trials.
• Analysis of treatment strategies combining PARP inhibitors with chemotherapy, immunotherapy, or as maintenance therapy.
• Examination of PARP inhibitor efficacy in patients with specific DDR mutations (e.g., BRCA, ATM, CDKN2A, mismatch repair genes).

Main Results:

• PARP inhibitors have demonstrated initial success in patients with germline BRCA mutations.
• Ongoing trials are evaluating PARP inhibitors in a broader spectrum of DDR mutations.
• Combinatorial approaches and maintenance therapies are being investigated to enhance treatment outcomes.

Conclusions:

• PARP inhibitors represent a significant advancement in pancreatic cancer treatment, targeting specific DNA damage repair (DDR) pathways.
• Expanding the use of PARP inhibitors to other DDR mutations holds potential for improving patient survival.
• Further research and clinical trials are crucial to optimize PARP inhibitor-based treatment strategies for pancreatic cancer.